Eli Lilly has cut the price for vials of its weight-loss drug Zepbound sold online and expanded the range of doses in an ...

Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

(Reuters) - Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, ...

Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound.  For many consumers, their insurance denies them ...

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...